CGRP vs Botox for Migraine: Understanding the Options

Two of the most discussed preventive options in migraine care today are CGRP-targeting therapies and Botox (onabotulinumtoxinA). If you have been researching CGRP vs Botox for migraine, you have probably noticed that information tends to swing between very technical and frustratingly vague. This article breaks down how each approach works, what makes someone a candidate, and what to track so you can have a sharper conversation with your clinician.

How CGRP Treatments Work

Calcitonin gene-related peptide, or CGRP, is a neuropeptide released in large amounts during a migraine attack. It causes blood vessels around the brain to widen and contributes directly to the pain signal. If you want a deeper primer on the biology, what is CGRP covers the mechanism in plain language.

CGRP-targeting medications fall into two broad categories:

• Monoclonal antibodies: These are injected (usually monthly or quarterly) and are designed to either neutralize CGRP itself or block the receptor it binds to. Because they are large molecules, they do not cross the blood-brain barrier to any significant degree and tend to have limited systemic side effects for most people.
• CGRP receptor antagonists (gepants): These are small-molecule oral medications. Some gepants are approved for prevention, others for acute treatment, and some for both. They work by blocking the same receptor pathway but are cleared from the body much faster than antibodies.

Both categories are specifically designed around the migraine mechanism, which is part of why they tend to have a cleaner side effect profile compared to older preventives originally developed for other conditions.

How Botox Works for Migraine

Botox is the brand name for onabotulinumtoxinA. When used for migraine prevention, it is injected into specific sites across the forehead, scalp, neck, and shoulders following a standardized protocol. The injections are typically repeated every 12 weeks.

The exact mechanism in migraine is still being studied, but the leading theory is that Botox blocks the release of neurotransmitters from peripheral nerve endings, which may reduce the sensitization that makes migraine attacks more frequent and severe over time. This is a different pathway from CGRP, which is part of why the two approaches can sometimes complement each other in complex cases.

Botox for migraine is primarily approved for chronic migraine, which most guidelines define as 15 or more headache days per month, with at least eight of those meeting migraine criteria. If you are unsure where you fall on the spectrum, episodic vs chronic migraine explains the distinction clearly.

Key Differences Side by Side

This table is a general orientation. Specific approvals and administration schedules vary by product and country. Your neurologist or headache specialist is the right source for guidance on which options apply to your situation.

Who Tends to Be Considered for Each

Clinicians consider a range of factors when recommending preventive treatment: migraine frequency, prior treatment history, coexisting conditions, insurance coverage, and patient preference for how often they want to administer or receive treatment.

CGRP antibodies may be considered for both episodic and chronic migraine when other preventives have not worked well. Gepants that are approved for prevention offer a daily oral option, which some patients prefer over injections.

Botox is generally reserved for chronic migraine and is often considered after two or more other preventives have not provided adequate relief, though this varies by payer and guideline.

Insurance prior authorization is a practical reality for both categories. Tracking your migraine days and their impact with consistent data makes prior authorization paperwork significantly easier to support. For a deeper look at the authorization process specifically for CGRP medications, CGRP prior authorization and renewal walks through what insurers typically require.

What to Track Before and During Treatment

Starting a preventive treatment without a baseline is like running a race without a starting line. You need before-and-after data to know if something is working.

The most useful things to track:

• Headache days per month: Total number of days with any headache, and how many meet full migraine criteria
• Severity: A simple 1-10 scale or a categorical mild/moderate/severe rating on each day
• Functional impact: How many days did you have to cancel plans, miss work, or reduce activity? The MIDAS and HIT-6 scales are standardized ways to quantify this, and you can use the HIT-6 calculator to score yourself before your next appointment
• Acute medication use: How often are you reaching for rescue medications? Frequent use can lead to medication overuse headache, which is worth understanding via the medication overuse headache article
• Response over time: The migraine reduction calculator can help you visualize whether your frequency is actually dropping

For a structured approach to evaluating whether a CGRP treatment is making a difference, measuring CGRP progress outlines the key markers to watch. And if you want to bring organized data to your doctor rather than a verbal summary, sharing your migraine log with your doctor has practical tips for making that handoff useful.

The Practical Reality of Cost and Access

Both CGRP treatments and Botox for migraine can be expensive without insurance, and access varies significantly depending on your plan, location, and diagnosis. CGRP treatment cost covers what affects price and how to approach assistance programs.

Cost, access, and personal preference are all legitimate factors in treatment decisions. So is your own history with previous preventives. The more complete a picture you can give your clinician, the better they can help you weigh the tradeoffs.

Using Tracking to Drive Better Decisions

Migraine Tracker: CGRP Log is built for exactly this kind of longitudinal data collection. Logging consistently over weeks and months means you arrive at every appointment with numbers, not impressions. Whether you are in the middle of a Botox trial, just started a CGRP antibody, or still deciding what to ask about, the data you collect now becomes the evidence your clinician needs to make the next call.

As always, any decision to start, stop, or switch a preventive treatment should be made with your neurologist or headache specialist. Nothing here is a substitute for that conversation.